Log in
NASDAQ:BOLD

Audentes Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$59.97
0.00 (0.00 %)
(As of 01/15/2020)
Add
Compare
Today's Range
$59.97
Now: $59.97▼
$59.97
50-Day Range
$59.97
MA: $59.97▼
$59.97
52-Week Range
$22.00
Now: $59.97▼
$60.00
VolumeN/A
Average Volume1.50 million shs
Market Capitalization$2.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.18
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Read More
Audentes Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.93 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BOLD
Previous Symbol
CUSIPN/A
CIK1628738
Webwww.audentestx.com
Phone415-818-1001
Employees207

Debt

Debt-to-Equity RatioN/A
Current Ratio12.80
Quick Ratio12.79

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($7.48) per share
Price / Book-8.02

Profitability

EPS (Most Recent Fiscal Year)($3.40)
Net Income$-128,820,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-38.00%

Miscellaneous

Outstanding Shares46,272,000
Market Cap$2.77 billion
Next Earnings DateN/A
OptionableOptionable

Receive BOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for BOLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Audentes Therapeutics (NASDAQ:BOLD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Audentes Therapeutics?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Audentes Therapeutics in the last year. There are currently 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Audentes Therapeutics.

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics Inc (NASDAQ:BOLD) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.07) by $0.07. During the same period in the prior year, the firm posted ($0.97) earnings per share.
View Audentes Therapeutics' earnings history.

What price target have analysts set for BOLD?

14 brokers have issued twelve-month price targets for Audentes Therapeutics' shares. Their forecasts range from $19.00 to $60.00. On average, they anticipate Audentes Therapeutics' share price to reach $54.45 in the next year. This suggests that the stock has a possible downside of 9.2%.
View analysts' price targets for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

Some companies that are related to Audentes Therapeutics include BIO-TECHNE (TECH), Repligen (RGEN), Neurocrine Biosciences (NBIX), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Vir Biotechnology (VIR), Denali Therapeutics (DNLI), Kodiak Sciences (KOD) and Halozyme Therapeutics (HALO).
View all competitors.

What other stocks do shareholders of Audentes Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Audentes Therapeutics investors own include Energy Transfer (ET), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Intel (INTC), Clovis Oncology (CLVS), AbbVie (ABBV), bluebird bio (BLUE), Ford Motor (F), Global Blood Therapeutics (GBT) and Myriad Genetics (MYGN).

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the following people:
  • Mr. Matthew R. Patterson, Co-Founder, Chairman & CEO (Age 47)
  • Ms. Natalie C. Holles, Pres & COO (Age 46)
  • Mr. Thomas P. Soloway, Exec. VP & CFO (Age 52)
  • Dr. John T. Gray, Sr. VP & Chief Scientific Officer (Age 56)
  • Mr. Andrew H. Chang, Director of Investor Relations

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

What is Audentes Therapeutics' stock price today?

One share of BOLD stock can currently be purchased for approximately $59.97.

How big of a company is Audentes Therapeutics?

Audentes Therapeutics has a market capitalization of $2.77 billion. The biotechnology company earns $-128,820,000.00 in net income (profit) each year or ($3.40) on an earnings per share basis. Audentes Therapeutics employs 207 workers across the globe.

What is Audentes Therapeutics' official website?

The official website for Audentes Therapeutics is www.audentestx.com.

How can I contact Audentes Therapeutics?

Audentes Therapeutics' mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company can be reached via phone at 415-818-1001 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.